

# Kathleen M Neuzil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145711/publications.pdf>

Version: 2024-02-01

82  
papers

16,551  
citations

172207

29  
h-index

62479

80  
g-index

93  
all docs

93  
docs citations

93  
times ranked

22774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. <i>Clinical Infectious Diseases</i> , 2022, 74, 352-358.	2.9	36
2	The Operational Feasibility of Vaccination Programs Targeting Influenza Risk Groups in the World Health Organization (WHO) African and South-East Asian Regions. <i>Clinical Infectious Diseases</i> , 2022, 74, 227-236.	2.9	3
3	The value of vaccine programme impact monitoring during the COVID-19 pandemic. <i>Lancet</i> , The, 2022, 399, 119-121.	6.3	6
4	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	13.9	418
5	Prevention and Control of COVID-19: Where do we go from here?. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	0
6	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	6.0	788
7	Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission. <i>Journal of Infectious Diseases</i> , 2022, 226, 225-235.	1.9	4
8	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. <i>JAMA Network Open</i> , 2022, 5, e2142796.	2.8	57
9	Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 679-691.	4.6	32
10	Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	0
11	Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	4
12	WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use. <i>Vaccine</i> , 2022, 40, 3506-3510.	1.7	20
13	Understanding COVID-19 through human challenge models. <i>Nature Medicine</i> , 2022, 28, 903-904.	15.2	4
14	Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. <i>Vaccine</i> , 2022, 40, 3253-3262.	1.7	3
15	Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, 402.	0.9	4
16	Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials. <i>Vaccine</i> , 2022, 40, 4339-4347.	1.7	1
17	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	2.0	63
18	Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results From 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011. <i>Clinical Infectious Diseases</i> , 2021, 72, e959-e969.	2.9	6

#	ARTICLE	IF	CITATIONS
19	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 80-82.	13.9	665
20	Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. <i>International Journal of Infectious Diseases</i> , 2021, 102, 517-523.	1.5	20
21	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	2.0	86
22	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Annals of Internal Medicine</i> , 2021, 174, 344-352.	2.0	73
23	The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 2257-2264.	2.9	376
24	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
25	Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics. <i>Vaccines</i> , 2021, 9, 281.	2.1	4
26	The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. <i>Vaccine</i> , 2021, 39, 2165-2176.	1.7	11
27	National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. <i>Eurosurveillance</i> , 2021, 26, .	3.9	23
28	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2259-2261.	13.9	603
29	Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. <i>International Journal of Infectious Diseases</i> , 2021, 108, 465-472.	1.5	14
30	Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. <i>Vaccine</i> , 2021, 39, 5037-5045.	1.7	17
31	Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. <i>Lancet, The</i> , 2021, 398, 675-684.	6.3	77
32	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	2.0	15
33	Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries. <i>Journal of Infectious Diseases</i> , 2021, 224, S770-S774.	1.9	16
34	Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. <i>New England Journal of Medicine</i> , 2021, 385, 1104-1115.	13.9	82
35	Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas. <i>Journal of Infectious Diseases</i> , 2021, 224, S781-S787.	1.9	19
36	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402

#	ARTICLE	IF	CITATIONS
37	A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. <i>MBio</i> , 2021, 12, e0224121.	1.8	21
38	LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19). <i>Open Forum Infectious Diseases</i> , 2021, 8, S804-S804.	0.4	1
39	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
40	Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e91-e103.	2.1	16
41	Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial. <i>Vaccine</i> , 2020, 38, 7526-7532.	1.7	1
42	Phase III study of COVID-19 RNA vaccine BNT162b1 in adults. <i>Nature</i> , 2020, 586, 589-593.	13.7	1,197
43	Early Insights From Clinical Trials of Typhoid Conjugate Vaccine. <i>Clinical Infectious Diseases</i> , 2020, 71, S155-S159.	2.9	4
44	Accelerating Development of SARS-CoV-2 Vaccines – The Role for Controlled Human Infection Models. <i>New England Journal of Medicine</i> , 2020, 383, e63.	13.9	73
45	Morbidity and Mortality of Typhoid Intestinal Perforation Among Children in Sub-Saharan Africa 1995–2019: A Scoping Review. <i>World Journal of Surgery</i> , 2020, 44, 2892-2902.	0.8	16
46	LB-17. Efficacy of Hydroxychloroquine (HCQ) for Post-exposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2020, 7, S851-S852.	0.4	0
47	A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. <i>Vaccine</i> , 2019, 37, 5777-5787.	1.7	41
48	Influenza vaccine programs for children in low- and middle-income countries: current status and way forward. <i>Expert Review of Vaccines</i> , 2019, 18, 711-724.	2.0	5
49	Maternal immunization in Malawi: A mixed methods study of community perceptions, programmatic considerations, and recommendations for future planning. <i>Vaccine</i> , 2019, 37, 4568-4575.	1.7	12
50	Reply to Skowronski and De Serres. <i>Clinical Infectious Diseases</i> , 2019, 69, 2231-2232.	2.9	1
51	The Impact of Influenza Vaccine: It's the Size of the Glass. <i>Clinical Infectious Diseases</i> , 2019, 69, 1854-1855.	2.9	2
52	Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. <i>Lancet Infectious Diseases</i> , 2019, 19, 728-739.	4.6	54
53	Influenza Immunization in Low- and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines. <i>Journal of Infectious Diseases</i> , 2019, 219, S97-S106.	1.9	43
54	Introduction of Typhoid Conjugate Vaccines in Africa and Asia. <i>Clinical Infectious Diseases</i> , 2019, 68, S27-S30.	2.9	19

#	ARTICLE	IF	CITATIONS
55	Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh. <i>Clinical Infectious Diseases</i> , 2019, 69, 2059-2070.	2.9	8
56	Future epidemiological and economic impacts of universal influenza vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20786-20792.	3.3	26
57	The Effect of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II, Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in Bangladeshi Children. <i>Clinical Infectious Diseases</i> , 2019, 69, 786-794.	2.9	20
58	Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh. <i>Clinical Infectious Diseases</i> , 2019, 69, 777-785.	2.9	18
59	How do we best prevent influenza in young children?. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 317-319.	5.2	1
60	Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants. <i>Journal of Infectious Diseases</i> , 2018, 218, 606-613.	1.9	23
61	Traditional cooking practices and preferences for stove features among women in rural Senegal: Informing improved cookstove design and interventions. <i>PLoS ONE</i> , 2018, 13, e0206822.	1.1	28
62	Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal. <i>Vaccine</i> , 2018, 36, 6424-6432.	1.7	11
63	Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1088-1096.	4.6	63
64	Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study. <i>Vaccine</i> , 2018, 36, 4054-4061.	1.7	16
65	Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. <i>Vaccine</i> , 2017, 35, 184-190.	1.7	37
66	Reaching every child with rotavirus vaccine: Report from the 10th African rotavirus symposium held in Bamako, Mali. <i>Vaccine</i> , 2017, 35, 5511-5518.	1.7	5
67	Estimating the full public health value of vaccination. <i>Vaccine</i> , 2017, 35, 6255-6263.	1.7	52
68	Influenza Vaccines for Older Persons: Progress and Pitfalls. <i>Journal of Infectious Diseases</i> , 2017, 216, 397-398.	1.9	1
69	Incidence of laboratory-confirmed influenza disease among infants under 6 months of age: a systematic review. <i>BMJ Open</i> , 2017, 7, e016526.	0.8	22
70	Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002282.	3.9	46
71	Maternal influenza immunization in Malawi: Piloting a maternal influenza immunization program costing tool by examining a prospective program. <i>PLoS ONE</i> , 2017, 12, e0190006.	1.1	16
72	Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. <i>The Lancet Global Health</i> , 2016, 4, e955-e965.	2.9	57

#	ARTICLE	IF	CITATIONS
73	The Art and Science of Delivering Influenza Vaccines. <i>Journal of Infectious Diseases</i> , 2016, 214, 1129-1131.	1.9	1
74	Preventing Shingles and Its Complications in Older Persons. <i>New England Journal of Medicine</i> , 2016, 375, 1079-1080.	13.9	13
75	Rotavirus vaccination and intussusception – Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2580-2589.	1.4	47
76	Progress toward a Respiratory Syncytial Virus Vaccine. <i>Vaccine Journal</i> , 2016, 23, 186-188.	3.2	61
77	Community-acquired diarrhoea in a world with rotavirus vaccine: a glimpse into the future. <i>The Lancet Global Health</i> , 2015, 3, e510-e511.	2.9	10
78	A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines. <i>Vaccine</i> , 2014, 32, A179-A184.	1.7	11
79	Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. <i>New England Journal of Medicine</i> , 2010, 362, 289-298.	13.9	800
80	Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2010, 376, 615-623.	6.3	660
81	Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2010, 376, 606-614.	6.3	626
82	Using social contact data to improve the overall effect estimate of a cluster-randomized influenza vaccination program in Senegal. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 0, , .	0.5	0